Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Effectiveness of Lurasidone in Schizophrenia or Schizoaffective Disorder
NCT00641745Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Mar 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of lurasidone in schizophrenia, schizoaffective disorder, sponsored by Sumitomo Pharma America. Started Mar 2008; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00641745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00641745.